TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Web-based Support for Caregivers of Veterans Undergoing Chemotherapy
Brief Summary: Given the growing strain on the Veterans Administration resulting from increasing caseloads of cancer patients, interventions are badly needed that assist patients in managing their illness, improve quality of life and avoid acute episodes that result in urgent care use and increased mortality. Previous studies have found that cancer patients undergoing chemotherapy can effectively manage their own symptoms when monitored using automated telephone calls. Such technology, however, may challenge the number of Veterans who lack social support and/or independence. The goal was to develop and test a technology that not only monitors patients automatically by telephone, but also gives them self management advice and engages a friend or family member to serve as a CarePartner willing to play a limited role in identifying patient symptoms and psychosocial needs to reinforce self management and provide social support. The investigators found that this technology indeed helped patients better control their symptoms, especially when a caregiver participated in the program along with them.


Options:
A: Intervention Type: BEHAVIORAL; Name: Mammography appointment reminders; telephone counseling; Assigned to Arm(s): N/A
B: Arm Label: CarePartners+; Type: EXPERIMENTAL; Interventions: Behavioral: Caregiver website | Arm Label: CarePartners-; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Caregiver website; Assigned to Arm(s): CarePartners+
C: Arm Label: ISTOP-ADE; Type: EXPERIMENTAL; Interventions: Other: ISTOP-ADE | Arm Label: Routine care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: ISTOP-ADE; Assigned to Arm(s): ISTOP-ADE
D: Intervention Type: PROCEDURE; Name: management of therapy complications; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: pain therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Double-blinded Trial Comparing Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis Relapses
Brief Summary: The efficacy of oral corticosteroids for the treatment of relapses of multiple sclerosis has not been proved. French neurologists treat such patients with intravenous corticosteroids. The aim of the study is to check if the efficacy of high dose oral methylprednisolone is similar to the efficacy intravenous (IV) prednisolone. The main criteria of efficacy is symptom recovery within 28 days after inclusion.


Options:
A: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 1.25 mg | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 0.5 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fingolimod 1.25 mg; Assigned to Arm(s): Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Fingolimod 0.5 mg; Assigned to Arm(s): Fingolimod 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: BG00012 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: BG00012, Drug: Placebo | Arm Label: BG00012 240 mg 3 Times Daily (TID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD); Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate | Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): BG00012 240 mg 3 Times Daily (TID), BG00012 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BG00012 240 mg Twice Daily (BID), Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate; Assigned to Arm(s): Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)
C: Arm Label: FTY720 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: FTY720 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720 0.5 mg, FTY720 1.25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: methylprednisolone PO; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone PO | Arm Label: methylprednisolone IV; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone IV | Intervention Type: DRUG; Name: methylprednisolone PO; Assigned to Arm(s): methylprednisolone PO | Intervention Type: DRUG; Name: methylprednisolone IV; Assigned to Arm(s): methylprednisolone IV

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Double-blinded Trial Comparing Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis Relapses
Brief Summary: The efficacy of oral corticosteroids for the treatment of relapses of multiple sclerosis has not been proved. French neurologists treat such patients with intravenous corticosteroids. The aim of the study is to check if the efficacy of high dose oral methylprednisolone is similar to the efficacy intravenous (IV) prednisolone. The main criteria of efficacy is symptom recovery within 28 days after inclusion.


Options:
A: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)
B: Arm Label: Siponimod (BAF312); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): Siponimod (BAF312) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: DAC HYP; Type: EXPERIMENTAL; Interventions: Drug: Midazolam, Other: Caffeine, Drug: S-warfarin, Other: Vitamin K, Drug: Omeprazole, Drug: Dextromethorphan, Biological: BIIB019 (Daclizumab) | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): DAC HYP | Intervention Type: OTHER; Name: Caffeine; Assigned to Arm(s): DAC HYP | Intervention Type: DRUG; Name: S-warfarin; Assigned to Arm(s): DAC HYP | Intervention Type: OTHER; Name: Vitamin K; Assigned to Arm(s): DAC HYP | Intervention Type: DRUG; Name: Omeprazole; Assigned to Arm(s): DAC HYP | Intervention Type: DRUG; Name: Dextromethorphan; Assigned to Arm(s): DAC HYP | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab); Assigned to Arm(s): DAC HYP
D: Arm Label: methylprednisolone PO; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone PO | Arm Label: methylprednisolone IV; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone IV | Intervention Type: DRUG; Name: methylprednisolone PO; Assigned to Arm(s): methylprednisolone PO | Intervention Type: DRUG; Name: methylprednisolone IV; Assigned to Arm(s): methylprednisolone IV

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Influence of Macrolide Maintenance Therapy and Bacterial Colonisation on Exacerbation Frequency and Progression of COPD, a Randomized Double-blind Placebo-controlled Trial
Brief Summary: To assess whether maintenance treatment with macrolide antibiotics in COPD patients with three or more exacerbations in the preceding year of inclusion can decrease the exacerbation rate in the year of treatment.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Doxycycline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: azithromycin (drug); Assigned to Arm(s): N/A
D: Arm Label: Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Influence of Macrolide Maintenance Therapy and Bacterial Colonisation on Exacerbation Frequency and Progression of COPD, a Randomized Double-blind Placebo-controlled Trial
Brief Summary: To assess whether maintenance treatment with macrolide antibiotics in COPD patients with three or more exacerbations in the preceding year of inclusion can decrease the exacerbation rate in the year of treatment.


Options:
A: Arm Label: Azithromycin, 250 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Macrolide Antibiotic (Azithromycin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macrolide Antibiotic (Azithromycin); Assigned to Arm(s): Azithromycin, 250 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: azithromycin (drug); Assigned to Arm(s): N/A
C: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin 250 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin 250 mg; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Influence of Macrolide Maintenance Therapy and Bacterial Colonisation on Exacerbation Frequency and Progression of COPD, a Randomized Double-blind Placebo-controlled Trial
Brief Summary: To assess whether maintenance treatment with macrolide antibiotics in COPD patients with three or more exacerbations in the preceding year of inclusion can decrease the exacerbation rate in the year of treatment.


Options:
A: Arm Label: Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Azythromycin (APRIL) and Prednisolone (OCELOT); Type: EXPERIMENTAL; Interventions: Drug: Azithromycin, Drug: Prednisolone | Arm Label: Azythromycin (APRIL) and Placebo (OCELOT); Type: EXPERIMENTAL; Interventions: Drug: Azithromycin, Drug: Placebo Prednisolone | Arm Label: Placebo (APRIL) and Prednisolone (OCELOT); Type: EXPERIMENTAL; Interventions: Drug: Prednisolone, Other: Placebo Azithromycin | Arm Label: Placebo (APRIL) and Placebo (OCELOT); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Azithromycin, Drug: Placebo Prednisolone | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azythromycin (APRIL) and Placebo (OCELOT), Azythromycin (APRIL) and Prednisolone (OCELOT) | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Azythromycin (APRIL) and Prednisolone (OCELOT), Placebo (APRIL) and Prednisolone (OCELOT) | Intervention Type: OTHER; Name: Placebo Azithromycin; Assigned to Arm(s): Placebo (APRIL) and Placebo (OCELOT), Placebo (APRIL) and Prednisolone (OCELOT) | Intervention Type: DRUG; Name: Placebo Prednisolone; Assigned to Arm(s): Azythromycin (APRIL) and Placebo (OCELOT), Placebo (APRIL) and Placebo (OCELOT)
C: Arm Label: Placebo and standard of care; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo and standard of care | Arm Label: Azithromycin and Standard of care; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin and standard of care | Intervention Type: DRUG; Name: Azithromycin and standard of care; Assigned to Arm(s): Azithromycin and Standard of care | Intervention Type: DRUG; Name: Placebo and standard of care; Assigned to Arm(s): Placebo and standard of care
D: Arm Label: Azithromycin, 250 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Macrolide Antibiotic (Azithromycin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macrolide Antibiotic (Azithromycin); Assigned to Arm(s): Azithromycin, 250 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The primary purpose of this study is to determine the safety, tolerability and pharmacokinetics of ABT-308 in healthy volunteers and patients with mild to moderate controlled asthma.


Options:
A: Arm Label: IV ABT-308 in asthmatics; Type: EXPERIMENTAL; Interventions: Drug: ABT-308, Drug: Placebo | Arm Label: SC ABT-308 in asthmatics; Type: EXPERIMENTAL; Interventions: Drug: ABT-308, Drug: Placebo | Arm Label: IV ABT-308 in healthy volunteers; Type: EXPERIMENTAL; Interventions: Drug: ABT-308, Drug: Placebo | Intervention Type: DRUG; Name: ABT-308; Assigned to Arm(s): IV ABT-308 in asthmatics, IV ABT-308 in healthy volunteers | Intervention Type: DRUG; Name: ABT-308; Assigned to Arm(s): SC ABT-308 in asthmatics | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): IV ABT-308 in asthmatics, IV ABT-308 in healthy volunteers | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): SC ABT-308 in asthmatics
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: QAX576 placebo | Arm Label: QAX576; Type: ACTIVE_COMPARATOR; Interventions: Drug: QAX576 | Intervention Type: DRUG; Name: QAX576 placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: QAX576; Assigned to Arm(s): QAX576
C: Arm Label: Oral Budesonide Suspension (OBS); Type: EXPERIMENTAL; Interventions: Drug: Oral Budesonide Suspension (OBS) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oral Budesonide Suspension (OBS); Assigned to Arm(s): Oral Budesonide Suspension (OBS) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: omalizumab; Type: EXPERIMENTAL; Interventions: Drug: omalizumab | Intervention Type: DRUG; Name: omalizumab; Assigned to Arm(s): omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Segment Elevation Myocardial Infarction The Eindhoven Reperfusion Study
Brief Summary: The DEBATER study is designed to determine the superiority of abciximab over no abciximab and to determine the superiority of drug eluting stents over bare metal stents in patients with acute myocardial infarction who undergo percutaneous coronary intervention.


Options:
A: Arm Label: Pharmacology Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bivalirudin, Drug: Unfractionated heparin | Arm Label: Stent Arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Bare metal stent, Device: Paclitaxel-eluting stent | Intervention Type: DRUG; Name: Bivalirudin; Assigned to Arm(s): Pharmacology Arm | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Pharmacology Arm | Intervention Type: DEVICE; Name: Bare metal stent; Assigned to Arm(s): Stent Arm | Intervention Type: DEVICE; Name: Paclitaxel-eluting stent; Assigned to Arm(s): Stent Arm
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: drug-eluting stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: bare-metal stent | Intervention Type: DEVICE; Name: drug-eluting stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: bare-metal stent; Assigned to Arm(s): 2
C: Arm Label: Bare metal stent (BMS); Type: ACTIVE_COMPARATOR; Interventions: Device: bare metal stent prokinetic, chrono, skylor or bluemedical | Arm Label: Drug eluting stent (DES); Type: ACTIVE_COMPARATOR; Interventions: Device: drug eluting stent (sirolimus eluting) - CYPHER stent | Arm Label: Abciximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abciximab | Arm Label: No abciximab; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Abciximab; Assigned to Arm(s): Abciximab | Intervention Type: DEVICE; Name: bare metal stent prokinetic, chrono, skylor or bluemedical; Assigned to Arm(s): Bare metal stent (BMS) | Intervention Type: DEVICE; Name: drug eluting stent (sirolimus eluting) - CYPHER stent; Assigned to Arm(s): Drug eluting stent (DES)
D: Arm Label: MGuard; Type: EXPERIMENTAL; Interventions: Device: MGuard | Arm Label: BMS or DES; Type: ACTIVE_COMPARATOR; Interventions: Device: Control BMS or DES | Intervention Type: DEVICE; Name: MGuard; Assigned to Arm(s): MGuard | Intervention Type: DEVICE; Name: Control BMS or DES; Assigned to Arm(s): BMS or DES

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).
Brief Summary: Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.


Options:
A: Arm Label: Certoparin; Type: EXPERIMENTAL; Interventions: Drug: Certoparin | Arm Label: Unfractionated Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated Heparin | Intervention Type: DRUG; Name: Certoparin; Assigned to Arm(s): Certoparin | Intervention Type: DRUG; Name: Unfractionated Heparin; Assigned to Arm(s): Unfractionated Heparin
B: Arm Label: Edoxaban group; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban, Drug: Low molecular weight heparin | Arm Label: Dalteparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Edoxaban; Assigned to Arm(s): Edoxaban group | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin group | Intervention Type: DRUG; Name: Low molecular weight heparin; Assigned to Arm(s): Edoxaban group
C: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression
D: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).
Brief Summary: Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.


Options:
A: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin overlapping with and followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin overlapping with and followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
B: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
C: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin
D: Arm Label: GFFC + LMWH; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparine | Intervention Type: DRUG; Name: Enoxaparine; Assigned to Arm(s): GFFC + LMWH

Answer: B